Fulgent Enterprise Value Over E B I T D A from 2010 to 2024
| FLGT Stock | USD 18.33 0.46 2.57% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (16.73) | Current Value (15.89) | Quarterly Volatility 86.15488714 |
Check Fulgent Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulgent Genetics' main balance sheet or income statement drivers, such as Discontinued Operations of 49.5 K, Depreciation And Amortization of 27.5 M or Interest Expense of 38.9 M, as well as many indicators such as Price To Sales Ratio of 2.83, Dividend Yield of 0.018 or PTB Ratio of 0.72. Fulgent financial statements analysis is a perfect complement when working with Fulgent Genetics Valuation or Volatility modules.
Fulgent | Enterprise Value Over E B I T D A |
Latest Fulgent Genetics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Fulgent Genetics over the last few years. It is Fulgent Genetics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fulgent Genetics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Fulgent Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (30.75) | |
| Coefficient Of Variation | (280.20) | |
| Mean Deviation | 63.53 | |
| Median | (16.73) | |
| Standard Deviation | 86.15 | |
| Sample Variance | 7,423 | |
| Range | 286 | |
| R-Value | 0.50 | |
| Mean Square Error | 5,993 | |
| R-Squared | 0.25 | |
| Significance | 0.06 | |
| Slope | 9.64 | |
| Total Sum of Squares | 103,917 |
Fulgent Enterprise Value Over E B I T D A History
About Fulgent Genetics Financial Statements
Fulgent Genetics shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Fulgent Genetics investors may analyze each financial statement separately, they are all interrelated. The changes in Fulgent Genetics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Fulgent Genetics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (16.73) | (15.89) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.